Scholarlink

<p>To understand the pathophysiology and etiology of COVID-19 patients with depressive symptoms, we investigated the presence of autoantibodies associated with neurological sequelae using salivary IgA antibody profiling in COVID-19 patients with depressive symptoms. We used a human protein microarray system to comprehensively measure IgA antibodies against human proteins in the saliva of three groups of participants: those who developed moderate or severe depressive symptoms 2–14&#xa0;months after SARS-CoV-2 infection (the ‘COVID-19 group’), those with no infection history who showed no depressive symptoms or only mild depressive symptoms (the ‘healthy control group’), and those with no infection history who were diagnosed with depression. As a result, 65 types of IgA antibodies recognizing human proteins were identified, all of which were present only in the COVID-19 group and not in the healthy control group. Several antigens recognized by these antibodies are associated with depressive symptoms. These findings suggest that distinctive salivary IgA antibody profiles may be associated with depressive symptoms following SARS-CoV-2 infection and could serve as candidate biomarkers for further investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Protein microarray-based profiling of salivary IgA antibodies against human proteins in COVID-19 patients with depressive symptoms

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月23日

查看全文
  • Yuichi Hikichi,
  • Kohei Kunieda

摘要

To understand the pathophysiology and etiology of COVID-19 patients with depressive symptoms, we investigated the presence of autoantibodies associated with neurological sequelae using salivary IgA antibody profiling in COVID-19 patients with depressive symptoms. We used a human protein microarray system to comprehensively measure IgA antibodies against human proteins in the saliva of three groups of participants: those who developed moderate or severe depressive symptoms 2–14 months after SARS-CoV-2 infection (the ‘COVID-19 group’), those with no infection history who showed no depressive symptoms or only mild depressive symptoms (the ‘healthy control group’), and those with no infection history who were diagnosed with depression. As a result, 65 types of IgA antibodies recognizing human proteins were identified, all of which were present only in the COVID-19 group and not in the healthy control group. Several antigens recognized by these antibodies are associated with depressive symptoms. These findings suggest that distinctive salivary IgA antibody profiles may be associated with depressive symptoms following SARS-CoV-2 infection and could serve as candidate biomarkers for further investigation.